The National Swedish Cord Blood Bank (NS-CBB) is linked to the Bone Marrow Donors Worldwide 1 register that admits international search and exchange with other non-commercial cord blood banks.
To run the NS-CBB, it is necessary to obtain funds for collection, storage and distribution of stem cells. Until now the NS-CBB has been financed primarily by the members of the Swedish Association of Local Authorities and Regions.
To give continued funding, the Swedish Association of Local Authorities and Regions requested an analysis to show whether the activities and costs of NS-CBB in relation to achieved effects expressed as survival and health-related quality of life (HRQoL) of patients transplanted with cord blood unit (CBU) from the NS-CBB were reasonable, and whether transplantation with CBU is cost-effective.
The aim of the analysis was to investigate costs and revenues associated with the NS-CBB in relation to potential survival effects and HRQoL, and to estimate the cost-effectiveness of umbilical stem cell transplantation.
The analysis was based on information available from authorities, interviews with NS-CBB staff and scientific publications.
The annual costs and revenues of NS-CBB, and the direct and indirect costs for patients who undergo transplantation with CBU were calculated. Costs are presented as Euro at 2015 price level.
Information about direct costs for transplantation with CBU were collected from a regional authority where the cost for children between 0 and 17 years of age was EUR 126 813, whereas the corresponding cost for patients older than 17 years of age was EUR 65 019.
Indirect costs or production losses were calculated based on information from Swedish authorities for patients or caregivers being off work owing to illness. For 1 year off work, the indirect costs were EUR 58 095.
Health effects could be expressed as quality-adjusted life years (QALYs) saved. A QALY is usually expressed as a value between 0, representing death or the worst possible condition, and 1, representing full health. 2, 3 No HRQoL data related to hematopoietic stem cell (HSC) transplantation expressed as QALYs were found. On the basis of studies with a nursing perspective, it can be concluded that HRQoL in patients who have undergone transplantation is heavily reduced during the first 6 months-1 year after transplantation.
The cost-effectiveness of umbilical cord stem cell transplantation was estimated in a hypothetical example for children aged 0-17 years.
Long-term survival data and survival prognosis for patients who received CBU from the bank are not yet available. At present, about 50 patients have undergone transplantation with CBUs from the NS-CBB. Among 23 patients who received CBUs from the NS-CBB in 2008 to 2013, 14 were still alive according to the Eurocord registry in September 2014 which corresponds to a survival rate of 61%. 4 A higher survival rate for patients who have received one unit (75%) compared with those who have received two units (56%) indicates better results for children, who in most cases are treated with one unit.
Cost-effectiveness can be calculated as cost per QALY according to the following ratio:
Cost CBU transplantation -Cost without transplantation QALY weight CBU transplantation -QALY weight without transplantation According to the NS-CBB budget, the annual costs were estimated at EUR 1 325 645 and the revenues at EUR 1 314 636 for 2016 (Table 1) based on a conservative assumption about five exported CBUs in 2016 and financing from the same sources as in 2015.
After transplantation, additional costs will occur. Probably, these costs will vary considerably depending on underlying disease, severity of disease, age and type of transplantation. An assumption was made that costs after transplantation will be half of the initial direct and indirect costs of transplantation. The estimated direct and indirect costs for two populations of different ages are shown in Table 2 .
The cost-effectiveness of stem cell transplantation was calculated as an illustrative example of patients between 0 and Vävnadsrådet is a body within SALAR that supports national coordination and uniform implementation of laws regulating blood, cells, tissues and organs. Vävnadsrådet is also acting to promote national health care on issues concerning donation.
17 years old. The calculation is based on the following data and assumptions:
• Ten patients, Swedish and international, will undergo transplantation with CBUs from the NS-CBB each year.
• The average age at transplantation will be 10 years.
• HRQoL, the first year after transplantation is assumed to be 0.3.
• HRQoL, during years 2-3 after transplantation is assumed to be 0.5.
• Six out of ten are supposed to survive the first 3 years after transplantation (survival rate 61%).
4
• Five out of ten are supposed to survive the first 4 years and then have the same survival probability as the general population in Sweden, that is, to an average age of 82 years 5 (expected survival for these patients from the fourth year: 82-10-3 years = 69 years).
• The average HRQoL among long-term survivors is supposed to be the same (0.82) as for the general population in Sweden in ages 18-84 years.
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• The total direct and indirect costs excluding cost of stem cells for 10 patients between 0 and 17 years of age are calculated at EUR 2.8 million (10 × 277 363).
• The total estimated cost for the NS-CBB is EUR 1 325 645 (Table 1) , that is, EUR 132 565 per unit if 10 units are used.
• The total cost for 10 patients between 0 and 17 years of age are calculated at EUR 4.1 million (2 773 630+1 325 000). This calculation assumes that no costs or QALYs are acquired for an alternative where there is no other active treatment available for the patients. Even if the prognosis for patients without transplantation is very poor with high mortality risk, there will probably occur palliative treatment costs until death and also some degree of HRQoL during the remaining life time. That means that the difference in cost between umbilical cord stem cell transplantation and no active treatment probably is lower than calculated, which indicates an even more favourable costeffectiveness for transplantation. The difference in HRQoL between umbilical cord stem cell transplantation and no active treatment is probably also lower than calculated indicating a less favourable cost-effectiveness. At the same time, the survival of patients without treatment will be substantially shorter. Taken together, these factors will still result in a low cost-effectiveness ratio for the transplantation alternative.
The cost-effectiveness of umbilical cord stem cell transplantation in Sweden is mainly depending on assumptions about long-term survival, costs after transplantation and HRQoL. The uncertainty is primarily related to the absence of data on long-term survival and HRQoL.
The mortality risk is highest during the first 2 years after transplantation, and will be rather stable and low after the third year. 7 It was therefore assumed that five of the six patients who survive the first 3 years after transplantation are long-term survivors with similar life expectancy and HRQoL as the general population.
The most important limitation of this report is the lack of data and the limited information related to the relatively few patients who have undergone transplantation with umbilical cord stem cells from the NS-CBB until now. The patient material is also heterogenous regarding age, underlying disease and number of received stem cell units.
Another limitation is the lack of information regarding costs for the alternative to transplantation with umbilical cord stem cells, and also survival and HRQoL when no other treatment choice is available. There is presently no specified level when a treatment could be considered as cost-effective in Sweden, although a threshold of SEK 655 000 (EUR 70 007) has been discussed. 8 In the UK, a cost-effectiveness ratio below GB £20 000 has been considered as cost-effective by the National Institute for Health and Care Excellence in 2013. 9 The calculated example thus indicates that transplantation with CBU is cost-effective when no other active treatment alternatives are available. The senstivity analysis indicates that this statement is valid even if the costs of transplantation should be twice as high as calculated from the available data.
In spite of the limitations, our conclusion is that umbilical cord stem cell transplantation in patients with severe life-threatening diseases is a cost-effective treatment with a relatively low cost-effectiveness ratio.
An altruistic biobank with the possibility to collect stem cells from donators of different ethnicity is important from a perspective of equality. Letter to the Editor
